Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.10
-0.01-0.24%
At close: -
$4.20
0.102.44%
After Hours: Mar 28, 4:55 PM EDT
Comments
Loading...
Lexeo Therapeutics Analyst Ratings and Price Targets | NASDAQ:LXEO | Benzinga
Lexeo Therapeutics Inc has a consensus price target of $22 based on the ratings of 7 analysts. The high is $28 issued by Baird on June 13, 2024. The low is $18 issued by Leerink Partners on March 24, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Chardan Capital, and RBC Capital on March 26, 2025, March 25, 2025, and March 25, 2025, respectively. With an average price target of $22.67 between HC Wainwright & Co., Chardan Capital, and RBC Capital, there's an implied 439.68% upside for Lexeo Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Chardan Capital
RBC Capital
Leerink Partners
Baird
1calculated from analyst ratings
Analyst Ratings for Lexeo Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/26/2025 | Buy Now | 447.62% | HC Wainwright & Co. | Mitchell Kapoor44% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2025 | Buy Now | 495.24% | Chardan Capital | Geulah Livshits46% | $25 → $25 | Maintains | Buy | Get Alert |
| 03/25/2025 | Buy Now | 376.19% | RBC Capital | Luca Issi42% | $24 → $20 | Maintains | Outperform | Get Alert |
| 03/24/2025 | Buy Now | 328.57% | Leerink Partners | Mani Foroohar49% | $19 → $18 | Maintains | Outperform | Get Alert |
| 01/21/2025 | Buy Now | 471.43% | RBC Capital | Luca Issi42% | $24 → $24 | Reiterates | Outperform → Outperform | Get Alert |
| 11/14/2024 | Buy Now | 447.62% | HC Wainwright & Co. | Mitchell Kapoor44% | $21 → $23 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | 495.24% | Chardan Capital | Geulah Livshits46% | $23 → $25 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | 352.38% | Leerink Partners | Mani Foroohar49% | $20 → $19 | Maintains | Outperform | Get Alert |
| 10/31/2024 | Buy Now | 400% | HC Wainwright & Co. | Mitchell Kapoor44% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 10/30/2024 | Buy Now | 447.62% | Chardan Capital | Geulah Livshits46% | $23 → $23 | Maintains | Buy | Get Alert |
| 10/25/2024 | Buy Now | 447.62% | Chardan Capital | Geulah Livshits46% | $23 → $23 | Maintains | Buy | Get Alert |
| 08/14/2024 | Buy Now | 447.62% | Chardan Capital | Geulah Livshits46% | $23 → $23 | Maintains | Buy | Get Alert |
| 08/13/2024 | Buy Now | 400% | HC Wainwright & Co. | Mitchell Kapoor44% | $22 → $21 | Maintains | Buy | Get Alert |
| 08/13/2024 | Buy Now | 471.43% | RBC Capital | Luca Issi42% | $24 → $24 | Reiterates | Outperform → Outperform | Get Alert |
| 07/16/2024 | Buy Now | 423.81% | HC Wainwright & Co. | Mitchell Kapoor44% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 07/15/2024 | Buy Now | 447.62% | Chardan Capital | Geulah Livshits46% | $23 → $23 | Maintains | Buy | Get Alert |
| 06/13/2024 | Buy Now | 566.67% | Baird | Brian Skorney57% | → $28 | Initiates | → Outperform | Get Alert |
| 06/06/2024 | Buy Now | 423.81% | HC Wainwright & Co. | Mitchell Kapoor44% | → $22 | Initiates | → Buy | Get Alert |
| 03/12/2024 | Buy Now | 471.43% | RBC Capital | Luca Issi42% | $22 → $24 | Maintains | Outperform | Get Alert |
| 11/28/2023 | Buy Now | 447.62% | Chardan Capital | Geulah Livshits46% | → $23 | Initiates | → Buy | Get Alert |
| 11/28/2023 | Buy Now | 352.38% | Leerink Partners | Mani Foroohar49% | → $19 | Initiates | → Outperform | Get Alert |
| 11/28/2023 | Buy Now | 423.81% | RBC Capital | Luca Issi42% | → $22 | Initiates | → Outperform | Get Alert |
| 11/28/2023 | Buy Now | 376.19% | Stifel | Paul Matteis43% | → $20 | Initiates | → Buy | Get Alert |
| 11/28/2023 | Buy Now | 376.19% | JP Morgan | Tessa Romero62% | → $20 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Lexeo Therapeutics (LXEO) stock?
The latest price target for Lexeo Therapeutics (NASDAQ:LXEO) was reported by HC Wainwright & Co. on March 26, 2025. The analyst firm set a price target for $23.00 expecting LXEO to rise to within 12 months (a possible 447.62% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lexeo Therapeutics (LXEO)?
The latest analyst rating for Lexeo Therapeutics (NASDAQ:LXEO) was provided by HC Wainwright & Co., and Lexeo Therapeutics reiterated their buy rating.
When was the last upgrade for Lexeo Therapeutics (LXEO)?
There is no last upgrade for Lexeo Therapeutics
When was the last downgrade for Lexeo Therapeutics (LXEO)?
There is no last downgrade for Lexeo Therapeutics.
When is the next analyst rating going to be posted or updated for Lexeo Therapeutics (LXEO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lexeo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lexeo Therapeutics was filed on March 26, 2025 so you should expect the next rating to be made available sometime around March 26, 2026.
Is the Analyst Rating Lexeo Therapeutics (LXEO) correct?
While ratings are subjective and will change, the latest Lexeo Therapeutics (LXEO) rating was a reiterated with a price target of $23.00 to $23.00. The current price Lexeo Therapeutics (LXEO) is trading at is $4.20, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.